10-Q: Amicus Therapeutics Reports Strong Q3 Sales Growth, Narrows Nine-Month Loss

Amicus Therapeutics, Inc. reported a significant increase in net product sales and a swing to net income for the third quarter, while substantially reducing its net loss for the first nine months of 2025.

Summary

• Net product sales for the three months ended September 30, 2025, increased by $27.5 million to $169.1 million, compared to $141.5 million in the prior year period.
• The company achieved a net income of $17.3 million for the three months ended September 30, 2025, a significant improvement from a net loss of $6.7 million in the same period of 2024.
• For the nine months ended September 30, 2025, net product sales grew by $70.4 million to $449.0 million, up from $378.6 million in the prior year period.
• The net loss for the nine months ended September 30, 2025, was reduced to $28.8 million, a substantial improvement from a net loss of $70.8 million in the same period of 2024.
• Galafold sales totaled $371.5 million for the nine months, an increase of $40.9 million year-over-year, while Pombiliti + Opfolda sales reached $77.5 million.
• Research and development expenses increased by $32.9 million to $112.1 million for the nine months, primarily due to a $30.0 million upfront payment for the Dimerix DMX-200 license.
• Selling, general, and administrative expenses rose by $29.7 million to $266.4 million for the nine months, driven by higher personnel costs, professional fees, and manufacturing expansion.
• Cash, cash equivalents, and marketable securities stood at $263.8 million as of September 30, 2025.
• The company licensed exclusive U.S. commercialization rights for Dimerix's Phase 3 drug candidate, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) and other indications, with potential milestones up to $560 million plus tiered royalties.
• A three-day trial concluded between Amicus and Aurobindo regarding generic Galafold patents, with post-trial briefings scheduled to conclude by December 16, 2025.

Sentiment

Score: 7

Explanation: The company demonstrated strong commercial growth for its key products, leading to a significant reduction in its nine-month net loss and a return to quarterly net income. The strategic licensing of DMX-200 adds a promising late-stage pipeline asset. While an accumulated deficit persists and SG&A expenses are rising, the positive operating cash flow and management's confidence in liquidity for the next 12 months indicate a positive trajectory, despite ongoing legal and R&D cost pressures.

Positives

• Net product sales increased by $27.5 million (19.5%) for the three months ended September 30, 2025, reaching $169.1 million, driven by growth in Galafold and Pombiliti + Opfolda.
• The company achieved a net income of $17.3 million for the three months ended September 30, 2025, a significant turnaround from a net loss of $6.7 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, was substantially reduced to $28.8 million, compared to $70.8 million in the same period of 2024.
• Gross profit increased by $21.4 million for the quarter and $62.1 million for the nine months, reflecting strong product sales performance.
• Positive cash flow from operating activities of $16.9 million for the nine months ended September 30, 2025, compared to net cash used of $30.0 million in the prior year.
• Successful licensing of DMX-200, a Phase 3 drug candidate for FSGS, expanding the company's pipeline with a novel mechanism of action.
• Continued commercial momentum and expansion for Galafold and Pombiliti + Opfolda, with multiple regulatory approvals and reimbursement agreements established globally.
• Management believes the current cash position of $263.8 million is sufficient to fund operations and ongoing research programs for at least the next 12 months.

Negatives

• The company still has an accumulated deficit of $2.8 billion as of September 30, 2025, and anticipates incurring losses through the fiscal year ending December 31, 2025.
• Selling, general, and administrative expenses increased significantly by $14.9 million for the quarter and $29.7 million for the nine months, due to higher professional fees and increased headcount.
• Research and development expenses for the nine months increased by $32.9 million, largely due to the $30.0 million upfront payment for the Dimerix license, impacting overall profitability.
• Ongoing Hatch-Waxman litigation with Aurobindo Pharma Limited regarding generic Galafold, with a decision pending after post-trial briefings.

Risks

• The scope, progress, results, and costs of clinical trials for drug candidates, including DMX-200, may vary.
• Manufacturing costs for drug supply, including Pombiliti, could fluctuate.
• Ability to obtain regulatory approvals and successfully commercialize pipeline candidates is uncertain.
• Costs, timing, and outcome of regulatory review for product candidates may be unpredictable.
• Changes in regulatory standards, laws, rules, or regulations, including tariffs, could impact manufacturing, transport, development, or commercialization.
• Commercialization activities, including product marketing, sales, and distribution, involve significant costs.
• The emergence of competing technologies and other adverse market developments could impact product success.
• Estimates regarding the potential market opportunity for products and product candidates may not be accurate.
• Ability to successfully commercialize Galafold and Pombiliti + Opfolda globally is subject to market acceptance and reimbursement.
• Ability to manufacture or supply sufficient clinical or commercial products, including Galafold and Pombiliti + Opfolda, may face challenges.
• Obtaining reimbursement for Galafold and Pombiliti + Opfolda is crucial and not guaranteed.
• Satisfying post-marketing commitments or requirements for continued regulatory approval is necessary.
• Costs of preparing, filing, prosecuting patent applications, and maintaining/enforcing intellectual property claims, including Hatch-Waxman litigation, are significant.
• The impact of ongoing or future litigation could be material.
• Acquiring or investing in businesses, products, and technologies, and integrating them, carries risks.
• Establishing licensing agreements, collaborations, or partnerships and realizing economic benefits from them is not assured.
• Costs associated with and ability to comply with emerging sustainability standards, including climate reporting requirements, may increase.
• Protecting information technology systems and maintaining global operations and supply chain without interruption is critical.
• Accurately forecasting revenue, operating expenditures, or other metrics impacting profitability can be challenging.
• Fluctuations in foreign currency exchange rates can impact financial results.
• Changes in accounting standards could affect financial reporting.

Future Outlook

The company anticipates incurring losses through the fiscal year ending December 31, 2025. It expects to continue incurring significant costs primarily due to research and development expenses, including clinical trials. Future capital requirements will depend on factors such as clinical trial progress, manufacturing costs, regulatory outcomes, commercialization activities, and intellectual property protection. The company believes its current cash position is sufficient to fund operations and ongoing research programs for at least the next 12 months, but potential business development, pipeline expansion, and manufacturing investments could impact long-term capital needs.

Management Comments

• We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases.
• We seek to deliver the highest quality therapies that have the potential to obsolete current treatments, provide significant benefits to patients, and be firstor best-in-class.
• We continue to see strong commercial momentum and expansion into additional geographies for Galafold.
• We are leveraging our global capabilities to develop and broaden our franchises in Fabry and Pompe disease, with focused discovery work on next generation therapies and novel technologies.
• We will continue to evaluate business development opportunities to build stockholder value and provide us with access to the financial, technical, clinical, commercial resources, and intellectual property necessary to develop and market technologies or products in rare and orphan diseases.
• We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, even if experience or future developments make it clear that projected results expressed or implied in such statements will not be realized, except as may be required by law.

Industry Context

Amicus Therapeutics operates in the specialized and high-growth rare disease biotechnology sector, focusing on therapies for conditions like Fabry and Pompe disease. The successful commercialization of Galafold and Pombiliti + Opfolda positions the company as a key player in these niche markets. The licensing of DMX-200 for FSGS, a rare kidney disorder with no specifically approved therapies in the U.S., demonstrates a strategic expansion into another high-unmet-need area. This move aligns with broader industry trends of companies seeking to acquire or license late-stage assets to diversify pipelines and leverage existing commercial infrastructure for rare disease treatments. The ongoing legal challenges related to generic competition for Galafold highlight the inherent intellectual property risks in the pharmaceutical industry, particularly for successful orphan drugs.

Management Changes

Corporate Governance

Legal Proceedings

• The company received Paragraph IV Certification Notice Letters from Teva Pharmaceuticals USA, Inc., Aurobindo Pharma Limited, and Lupin Limited in connection with Abbreviated New Drug Applications (ANDA) for generic Galafold.
• In November 2022, the company filed four lawsuits against Teva, Lupin, and Aurobindo for infringement of its Orange Book-listed patents.
• A stipulation order to stay litigation with respect to Lupin was ordered in the fourth quarter of 2023, and the stay remains in place.
• In October 2024, the company entered into a non-exclusive, non-transferable, royalty-free, fully paid-up license with Teva, allowing Teva to market its generic version of Galafold in the United States beginning on January 30, 2037, or earlier under certain circumstances. This litigation has been terminated.
• From September 29, 2025, to October 1, 2025, the U.S. District Court for the District of Delaware held a three-day trial to hear evidence and argument regarding disputed patent issues between Aurobindo and the company. Post-trial briefing is scheduled to conclude by December 16, 2025, with a decision expected thereafter.

Stakeholder Impact

• **Shareholders**: Positive impact from increased product sales, reduced net loss, and a strategic pipeline expansion with DMX-200. However, ongoing R&D and SG&A expenses, along with legal proceedings, could introduce volatility. The ATM program provides a potential source of dilution.
• **Patients**: Positive impact from continued availability and global expansion of Galafold and Pombiliti + Opfolda, offering treatments for rare diseases. The DMX-200 license offers hope for a new therapy for FSGS, a condition with high unmet medical need.
• **Employees**: Increased headcount to support product supply and commercialization, as indicated by higher personnel costs in SG&A, suggests job growth. The 2025 Equity Incentive Plan provides ongoing compensation and retention incentives.
• **Customers (Distributors/Pharmacies)**: Continued strong demand for Galafold and Pombiliti + Opfolda, leading to increased sales volume.
• **Suppliers (WuXi Biologics, Dimerix)**: WuXi Biologics continues as a manufacturing partner, with updated agreements. Dimerix benefits from the upfront payment and potential milestone payments and royalties from the DMX-200 license.

Next Steps

• Continue regulatory submissions and reimbursement processes for Pombiliti + Opfolda with global health authorities.
• Dimerix will continue to fund and execute the Phase 3 ACTION3 study for DMX-200.
• Amicus will be responsible for submission and maintenance of the regulatory dossier for DMX-200 in the United States, as well as all costs of commercialization activities.
• Amicus and Dimerix will continue to align on the development and commercialization of DMX-200 in FSGS in the U.S. through a Joint Steering Committee.
• Continue discovery for next-generation genetic medicines for Fabry and Pompe disease.
• Evaluate business development opportunities, including collaborations, alliances, business combinations, partnerships, in-licensing or out-licensing assets, or acquisitions.
• Submit post-trial briefing in the Aurobindo litigation by December 16, 2025, with a decision from the District Court expected thereafter.
• Update the market by filing a Form 8-K within four business days once the District Court issues its substantive decision on the Aurobindo litigation.

Key Dates

Recommendation

Amicus Therapeutics demonstrates strong commercial execution with significant revenue growth for both Galafold and Pombiliti + Opfolda, leading to a positive net income for the quarter and a substantially reduced net loss for the nine-month period. The licensing of DMX-200 for FSGS represents a strategic pipeline expansion into a high-unmet-need area. While the company still carries a substantial accumulated deficit and faces ongoing R&D and SG&A cost pressures, the positive operating cash flow and management's confidence in near-term liquidity are encouraging. The ongoing Aurobindo litigation introduces some uncertainty, but the Teva settlement provides clarity on a key generic threat. Given the mixed financial picture—improving but still with challenges—and the strategic growth initiatives, a 'Hold' recommendation is appropriate for investors to observe continued progress in profitability and pipeline development.

Keywords

Rare Diseases, Fabry Disease, Pompe Disease, FSGS, Galafold, Pombiliti + Opfolda, DMX-200, Biotechnology, SEC Filing, 10-Q, Pharmaceuticals, Orphan Drug, Clinical Trials, Commercialization, Licensing Agreement